Why the study?
Does valproate use cause brain pseudoatrophy and gray matter volume reductions in patients with a mitochondrial DNA mutation?
Does valproate use cause brain pseudoatrophy and gray matter volume reductions in patients with a mitochondrial DNA mutation?
Valproate use may be associated with brain pseudoatrophy and mental regression, particularly in the context of a mitochondrial DNA mutation.
Answers are grounded in this paper and cite their sources.
May warrant caution with valproate in mtDNA mutation carriers; leaves open causality of gray matter reductions.
Valproate use associated with frontal and cerebellar gray matter volume reductions: A voxel‐based morphometry study,
No takes yet. Share an insight, caveat, or question.
Galimberti et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: